Overview

Efficacy of VIldagliptin aS an Add-on Therapy to Metformin Compared to Metformin Up-TitratION in Chinese Patients With Type 2 Diabetes.(VISION)

Status:
Completed

Trial end date:
2013-12-01

Target enrollment:

Participant gender:

Summary

This is an open-labeled, randomized, multicenter, prospective, parallel group, interventional study to demonstrate the effectiveness of 24 weeks treatment with Vildagliptin 50mg bid as add on to metformin 500 mg bid compared to metformin up to 1000 mg bid in Chinese patients with type 2 diabetes inadequately controlled on sub maximal dosage metformin monotherapy.

Phase:

Phase 4

Details

Lead Sponsor:

Novartis Pharmaceuticals

Treatments:

Metformin
Vildagliptin